What Is Methylphenidate and How Does It Work in ADHD?

When ADHD medication is discussed, brand names come up most of the time. Yet what matters is not the name on the box that comes out of the pharmacy but the active substance inside it. Methylphenidate is the most commonly used active substance in ADHD, in Türkiye and in the world, and the shared content of several different products on the market.

This article explains what the medication is, what it does and what it does not do. Which medication will be used by whom, what the dose will be and how long it will last are the physician's decisions; none of those decisions is made here.

What it does in the brain

Nerve cells talk to one another by releasing chemical messengers into the small gap between them. After the messenger has done its job it is taken back up and removed from the environment. Methylphenidate slows this reuptake: dopamine and noradrenaline stay longer in the gap, and the signal is transmitted more strongly.

One of the places where these two messengers are concentrated is the network of executive functions, which directs attention and brakes impulse. This is exactly the network that struggles in ADHD. It is also the target of the medication.

Two sentences need to be kept apart: the medication does not create attention, it makes the management of attention easier. It does not load information, it does not do the work in your place, it does not turn a job you do not know how to do into one you know.

Methylphenidate is not a teacher, it is a pair of glasses. It does not teach seeing, it sharpens the sight that is already there.

For me this distinction settled late. You come from a place where the medication is described like a "success pill," and when you see the real effect you feel something odd: life does not get easier, you are simply able to stand behind your own decisions. I wrote about this difference in expectations in detail in the article on what to expect from medication treatment.

What the evidence says

The network meta-analysis by Cortese and colleagues (2018), which combines 133 randomized controlled trials, places methylphenidate first for children and adolescents, and amphetamine derivatives first for adults, in terms of the balance of efficacy and tolerability. This does not mean "the best for everyone"; it means the option that gives the most consistent result in group averages.

The World Federation consensus statement (Faraone et al., 2021) notes that the effect of ADHD medications is among the best-documented treatment effects in medicine. The same text also says that this effect is on the symptoms, and that it does not mean an automatic improvement across the whole of life.

The NICE guideline (NG87) counts medication treatment in adults among the first options if the symptoms cause loss of function, and recommends regular follow-up for everyone who starts medication. The European consensus statement (Kooij et al., 2019) stresses the same point: the medication is not a treatment plan on its own, it is a part of the plan.

Short-acting and long-acting forms

The most talked-about side of methylphenidate in daily life is how long it works. The products on the market divide into two in this respect.

Short-acting (immediate-release) forms. Its effect begins a short time after it is taken, lasts a few hours and then wears off. More than one dose a day may be needed. The advantage is that where the effect begins and ends is visible; the disadvantage is the ups and downs through the day and the burden of remembering the dose. In a picture where remembering is difficult, three doses a day is a problem in itself.

Long-acting (controlled-release) forms. They are designed to spread the active substance through the day. A single dose taken in the morning aims at a flatter curve through the day. Because of the structure of the tablet, splitting, chewing or crushing it breaks this design.

Which one suits whom varies with the hours of the day in which function is needed, the sleep pattern, the side effects and the person's preference. This is not a matter of "good medication, bad medication"; it is a matter of matching.

When does the effect begin, how long does it last

The most distinctive feature of stimulants is that the effect shows quickly. There is no waiting period of weeks as with antidepressants; when the right dose is found the difference can be felt the same day.

This has a side effect: a person wants to make the final decision from the first day. Yet what is seen on the first day is often the unfinished state of dose adjustment. I described this process in detail in the article on how long ADHD medication takes to work.

The ending of the effect is just as important. When the effect wears off at the end of the day, the symptoms feeling more pronounced for a while is called rebound, and this does not mean the medication is doing harm.

What it does not solve

This section would leave the article incomplete if I did not write it, because most of the disappointment is here.

It does not build a system. The medication does not fill in a calendar that does not exist. You still need to decide what to do and when. This is also why the question of medication or therapy is meaningless: the two look after different jobs.

It does not repair the past. The mark left by years of being called "lazy" is not something that improves with a dose. That part has to do with time, and often with a process.

It does not change personality. This is one of the fears heard most often; I covered it in a separate article. In short: what gives the feeling of flattening is generally a high dose, and this is a matter to be discussed through dose adjustment.

It does not close the question of addiction by itself. Use under physician supervision at the recommended dose is not the same as misuse. I wrote this distinction, with its sources, in the article on addiction.

The prescription situation in Türkiye

Medications containing methylphenidate are controlled in Türkiye. According to the Ministry of Health's circular no. 2010/26 and the regulations that followed, these medications are written on a red prescription, and the physicians who can write the prescription are limited: specialists in adult psychiatry and in child and adolescent psychiatry.

The number of boxes that can be written per prescription is also limited. These rules can be updated over time, so take the framework here as information; ask your physician and your pharmacy about current practice.

In practice the problem encountered most often is not the rule but availability. From time to time the medication cannot be found in pharmacies, and for someone whose treatment is ongoing this means a serious interruption.

For the full list of side effects and which of them improve with adjustment, you can look at the article on side effects.

Why follow-up is needed

After medication is started, the control appointments are not a formality. What is looked at in follow-up is generally the following:

• The change in symptoms: what has improved, what has stayed the same.
• Sleep pattern and appetite.
• Blood pressure and pulse.
• Anxiety, restlessness or a change in mood.
• Whether the timing of the dose fits into daily life.

It is hard to remember these from memory. Going to the check-up with short notes I had kept for two weeks moved the appointment to a completely different place: instead of "it was fine, I think," I had dates and times in my hand.

What stays with me

There are two mistakes made most often when describing methylphenidate. The first is to describe it as a character corrector. The second is to close the subject by saying "it's a drug after all." Both come from the same place: not knowing what the medication does.

What it does is actually rather modest. In the circuit that directs attention, it prolongs the effect of two messengers. You still do everything else yourself; it is just that this time you have a ground on which to stand behind your own decisions.

The decision itself is not made here. This article is information; prescription, dose and duration are things to discuss with your physician.